Phase III Trial of Sirolimus in IBM
Phase III Trial of Sirolimus in IBM
Active, not recruiting · NCT04789070 · Registry updated 2026-01-14Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase III Trial of Sirolimus in IBM | inclusion body myositis, muscle tissue disorder, musculoskeletal system disorder, myositis disease, nervous system disorder, neuromuscular disease | Active, not recruiting | Phase 3 | 2026-01-14 | NCT04789070 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| The Perron Institute | 1 |
| University of Kansas Medical Center | 169 |
10 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Austin Health | Melbourne | Australia | 3 |
| Concord Repatriation Hospital | Sydney | Australia | 1 |
| Johns Hopkins University | Baltimore | United States | 49 |
| Leiden University Medical Center | Leiden | Netherlands | 54 |
| Perron Institute | Perth | Australia | 1 |
| Royal Adelaide Hospital | Adelaide | Australia | 10 |
| Royal Brisbane and Women's Hospital | Brisbane | Australia | 2 |
| Royal Northshore Hospital | Sydney | Australia | 1 |
| St Vincent's Hospital | Melbourne | Australia | 3 |
| University of Kansas Medical Center | Kansas City | United States | 240 |